SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Highlights Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Market Closed - Hong Kong S.E. Other stock markets 01:38:42 28/06/2024 pm IST			5-day change	1st Jan Change
1.79 ^HKD	+0.56%		-1.10%	-29.80%

21/06	Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial	MT
21/06	Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Fudan Zhangjiang Bio-Pharmaceutical Enrolls First Patient for Glioma Drug Trial	21/06	MT
Shanghai Fudan Zhangjiang Bio-Pharmaceutical Terminates Libod Marketing Agreement	21/06	MT
Shanghai Fudan-Zhangjiang Terminates Marketing Agreement	20/06	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Announces First Patient Enrolled in Confirmatory Clinical Trial of Aminolevulinic Acid Hydrochloride Powder for Oral Solution for Intraoperative Visualisation of Glioma	20/06	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	01/04	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	28/03	CI
Fudan-Zhangjiang Bio's 2023 Profit Falls	26/02	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	18/12	CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	13/11	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	13/11	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	08/11	CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	31/23/31	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23/23/23	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	20/23/20	CI
Fudan-Zhangjiang Bio Swings to Profit in H1	11/23/11	MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors	09/23/09	CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	02/23/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Highlights

Filters